Valuation: Axonics, Inc.

Capitalization 3.63B 3.08B 2.88B 2.7B 4.99B 330B 5.47B 33.67B 12.99B 155B 13.61B 13.32B 562B P/E ratio 2022
-48.9x
P/E ratio 2023 -502x
Enterprise value 3.31B 2.81B 2.63B 2.47B 4.55B 301B 4.99B 30.72B 11.85B 141B 12.42B 12.16B 512B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
3 years 47.59
Extreme 47.59
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 2013-09-30
Director of Finance/CFO 40 2023-10-01
Chief Operating Officer 46 2018-07-31
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Chairman 54 2020-04-28
Director/Board Member 73 2019-04-07
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.75%-.--%-.--%+18.68% 3.63B
-1.02%+0.70%-5.64%+46.64% 134B
+1.08%-2.40%+24.36%+13.03% 13.76B
+1.82%+6.45%-21.07%+167.80% 6.53B
+2.02%-0.44%-32.86%-62.56% 6.02B
-3.14%-17.80%-38.83%-54.46% 3.36B
+0.22%+1.85%+57.06%+35.91% 2.83B
-2.92%+1.14%-3.81%-13.70% 2.2B
-0.37%-0.78%-20.37%-28.22% 1.56B
-1.77%-3.59%-43.07%-50.15% 1.49B
Average -0.33%-1.77%-8.42%+7.30% 17.59B
Weighted average by Cap. -0.65%+0.09%-4.73%+39.85%
See all sector performances

Financials

2022 2023
Net sales 274M 232M 217M 204M 376M 24.88B 412M 2.54B 980M 11.69B 1.03B 1.01B 42.37B 366M 311M 291M 273M 504M 33.31B 552M 3.4B 1.31B 15.65B 1.37B 1.35B 56.72B
Net income -59.7M -50.7M -47.43M -44.46M -82.05M -5.43B -89.94M -554M -214M -2.55B -224M -219M -9.24B -6.09M -5.17M -4.84M -4.53M -8.37M -553M -9.17M -56.5M -21.8M -260M -22.83M -22.36M -943M
Net Debt -348M -296M -277M -259M -478M -31.65B -524M -3.23B -1.25B -14.87B -1.31B -1.28B -53.89B -317M -270M -252M -236M -436M -28.85B -478M -2.95B -1.14B -13.55B -1.19B -1.17B -49.13B
More financial data * Estimated data
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
More about the company